For gene therapies, FDA drafts trial guidance, finalizes "sameness" for orphan exclusivity

A new draft guidance from the US Food and Drug Administration (FDA) gives cell and gene therapy developers a detailed framework for the conduct of umbrella trials, offering the potential for enhanced speed and efficiency in early-stage clinical trials.